QT Interval Prolongation in TB/HIV Coinfection: Drug Interactions, Risks, and Clinical Recommendations
DOI:
https://doi.org/10.52692/1857-0011.2024.2-79.31Keywords:
QT interval prolongation, TB/HIV coinfection, cardiotoxicity, drug interactions, monitoringAbstract
TB/HIV coinfection is associated with a high risk of QT interval prolongation during multi - drug therapy, increasing the likelihood of severe cardiotoxic complications. This article analyzes the mechanisms of drug - induced QT interval prolongation in coinfected patients, including Bedaquiline, Moxifloxacin , Clofazeminum and antiretroviral drugs, and discusses strategies to prevent arrhythmias. Recommendations include QT interval monitoring, electrolyte balance control, and the use of genetic testing for a personalized therapeutic approach. This study aims to improve the safety and efficacy of treatment, contributing to reduced mortality among TB/HIV coinfected patients.
References
Borisov S, Keertan D, Martin E. Bedaquiline Improves Outcomes Among Patients with Multidrug-Resistant Tuberculosis: A Multicentre Study. The European Respiratory Journal, vol. 49, no. 5, 2017, p. 1700387,
Inesa N, Rita M, Aelita P, Stephanie Y, Vishwanath V. HIV–TB Coinfection: Current Therapeutic Approaches and Drug Interactions. PubMed, 2024 Feb 21;16(3):321.
K S Sachdeva, A K Bhatnagar, A Bhaskar , N Singla, R Sridhar, B Ramraj, A Athawale, R Solanki, S R Baruah, Y Patel, R Ramachandran, C Padmapriyadarsini. QTc prolongation with bedaquiline treatment for drug- resistant pulmonary TB in a programmatic setting. PubMed, 2023.
ICH Guideline E14/S7B: Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential - Questions and Answers - Step 5, 2022.
Mohammed Ibn-Mas’ud D, Safah K, Farah W, Lina M N, Unwam E, Jumbo & AE. What is polypharmacy in people living with HIV/AIDS? A systematic review. AIDS Research and Therapy volume 19, Article number: 37 (2022).
Martîniuс, С. I., and Pisarenсo, S. V. Prolongation of QT Interval During Chemotherapy of Pulmonary Tuberculosis. Tuberculosis and Lung Diseases, vol. 96, no. 6, 2018, p. 66.
Sharon I, Kathy B, Eric N, Alison D G, James M. QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study. Open Forum Infect Dis. 2021 Aug 1;8(8):ofab413.
Graeme M, James C M, James N, Gary M. Management of Active Tuberculosis in Adults with HIV. The Lancet HIV, 2019 Jul;6(7):e463-e474.
NCI Common Terminology Criteria for Adverse Events, version 4.03, 14 June 2010. National Institutes of Health National Cancer Institute.
Ostroumova, O. D., and Goloborodova, I. V. Drug- Induced QT Interval Prolongation: Prevalence, Risk Factors, Treatment, and Prevention. Consilium Medicum, vol. 21, no. 5, 2019, pp. 62-67,
Richard A M, Vincent C, Rajesh T G, Daniel RK, Henry S. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PubMed, 2012;7(9):e44793.
Protocol Clinic National ”Tuberculoza la Adult”. (Ediția VI) PCN-123. Chișinău, 2024, p. 208.
Protocol Clinic Național ”Infecția cu HIV la adult și adolescent” (ediția III) PCN – 211, Chișinău, 2022
WHO Operational Handbook on Tuberculosis. Module 6: Tuberculosis and Comorbidities. 2nd ed., World Health Organization, 2024, Licence: CC BY- NC-SA 3.0 IGO.
World Health Organization (WHO). Global Tuberculosis Report 2024. 29 October 2024. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024.
Downloads
Published
License
Copyright (c) 2025 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
